Inclusion Criteria:

          -  Part 1: advanced stage solid tumors; Part 2: non-small cell lung cancer (NSCLC),
             pancreatic cancer and cutaneous melanoma

          -  Eastern cooperative oncology group (ECOG) performance score of 0 or 1

          -  Adequate organ function as defined in the protocol

          -  A woman of childbearing potential must have a negative highly sensitive serum
             (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at Screening and a
             negative urine pregnancy test prior to the first dose of study drug

          -  During the study and for at least 120 days after receiving the last dose of study
             drug, in addition to the highly effective method of contraception, a man who is
             sexually active with a woman of childbearing potential must agree to use a barrier
             method of contraception (example [eg.], condom with spermicidal
             foam/gel/film/cream/suppository), or who is sexually active with a woman who is
             pregnant must use a condom

        Exclusion Criteria:

          -  Malignancy other than the disease under study within 2 years before screening
             (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ
             of the cervix, or malignancy that in the opinion of the investigator, with
             concurrence with the sponsor's medical monitor, is considered cured with minimal risk
             of recurrence)

          -  Symptomatic brain metastases; asymptomatic brain metastases are allowed provided that
             they have been treated, have been stable for greater than (>) 6 weeks as documented
             by radiographic imaging, and do not require prolonged (>14 days) systemic
             corticosteroid therapy

          -  Treatment with any local or systemic anti-neoplastic therapy or investigational
             anticancer agent within 14 days or 4 half-lives, whichever is longer, up to a maximum
             wash-out period of 28 days prior to the initiation of study drug administration

          -  Toxicities from previous anti-cancer therapies have not resolved to baseline levels
             or to Grade 1 or less except for alopecia and peripheral neuropathy

          -  Major surgery (eg., requiring general anesthesia) within 3 weeks before screening, or
             will not have fully recovered from surgery, or has surgery planned during the time
             the subject is expected to participate in the study